Detalhe da pesquisa
1.
Characterization and biodistribution of under-employed gene therapy vector AAV7.
J Virol
; 97(11): e0116323, 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37843374
2.
GluK2 Is a Target for Gene Therapy in Drug-Resistant Temporal Lobe Epilepsy.
Ann Neurol
; 94(4): 745-761, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37341588
3.
Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors.
J Virol
; 92(20)2018 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30089698
4.
TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy.
Cell Immunol
; 346: 103997, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31703913
5.
Deamidation of Amino Acids on the Surface of Adeno-Associated Virus Capsids Leads to Charge Heterogeneity and Altered Vector Function.
Mol Ther
; 26(12): 2848-2862, 2018 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30343890
6.
Significant Differences in Capsid Properties and Potency Between Adeno-Associated Virus Vectors Produced in Sf9 and HEK293 Cells.
Hum Gene Ther
; 34(19-20): 1003-1021, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37597192
7.
Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors.
Front Neurol
; 13: 1051559, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36452163
8.
Isolating Human Monoclonal Antibodies Against Adeno-Associated Virus From Donors With Pre-existing Immunity.
Front Immunol
; 11: 1135, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32733434
9.
Adeno-associated virus serotypes 1, 8, and 9 share conserved mechanisms for anterograde and retrograde axonal transport.
Hum Gene Ther
; 25(8): 705-20, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24694006
10.
Lessons learned from the clinical development and market authorization of Glybera.
Hum Gene Ther Clin Dev
; 24(2): 55-64, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23808604